NASDAQ:CRBP Corbus Pharmaceuticals (CRBP) Stock Price, News & Analysis $6.92 -0.22 (-3.08%) Closing price 04:00 PM EasternExtended Trading$7.05 +0.13 (+1.86%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Corbus Pharmaceuticals Stock (NASDAQ:CRBP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Corbus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$6.88▼$7.1850-Day Range$6.92▼$11.4852-Week Range$6.32▼$20.56Volume932,003 shsAverage Volume460,419 shsMarket Capitalization$129.20 millionP/E RatioN/ADividend YieldN/APrice Target$41.00Consensus RatingModerate Buy Company Overview Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research programs are designed to target biological pathways involved in tumor growth, immune regulation and tissue fibrosis. Corbus’s oncology pipeline includes CRB-701, an antibody-drug conjugate designed to target Nectin-4, a protein expressed on several solid tumors. The company is also developing CRB-601, an investigational monoclonal antibody directed at the alpha v beta 6 integrin, a target associated with tumor biology and fibrotic disease. These programs are being evaluated as potential treatments for patients with difficult-to-treat cancers. The company was founded in 2009 and initially focused on therapies for inflammatory and fibrotic diseases, including systemic sclerosis and cystic fibrosis. Corbus later shifted its strategic emphasis toward oncology and expanded its pipeline through internal research and licensing activities. Its operations and clinical development activities are centered in the United States, with research and development programs intended to serve international patient populations. Yuval Cohen, Ph.D., serves as Corbus Pharmaceuticals’ chief executive officer and has led the company through its transition from an inflammation-focused biotechnology company to an oncology-focused developer.AI Generated. May Contain Errors. Read More Corbus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreCRBP MarketRank™: Corbus Pharmaceuticals scored higher than 61% of companies evaluated by MarketBeat, and ranked 351st out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCorbus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialCorbus Pharmaceuticals has a consensus price target of $41.00, representing about 492.5% upside from its current price of $6.92.Amount of Analyst CoverageCorbus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Corbus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Corbus Pharmaceuticals are expected to decrease in the coming year, from ($5.62) to ($6.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corbus Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corbus Pharmaceuticals is -1.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorbus Pharmaceuticals has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Corbus Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.31% of the float of Corbus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorbus Pharmaceuticals has a short interest ratio ("days to cover") of 1.54, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corbus Pharmaceuticals has recently increased by 22.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCorbus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorbus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentCorbus Pharmaceuticals has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Corbus Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest15 people have searched for CRBP on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Corbus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Corbus Pharmaceuticals insiders have sold 1,130.13% more of their company's stock than they have bought. Specifically, they have bought $25,038.00 in company stock and sold $308,000.00 in company stock.Percentage Held by Insiders3.50% of the stock of Corbus Pharmaceuticals is held by insiders.Percentage Held by Institutions64.64% of the stock of Corbus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Corbus Pharmaceuticals' insider trading history. Receive CRBP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRBP Stock News HeadlinesWedbush Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)September 17, 2026 | theglobeandmail.comCorbus Pharmaceuticals (NASDAQ:CRBP) Director Yong Ben Sells 2,000 SharesSeptember 16, 2026 | insidertrades.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 28 at 1:00 AM | Porter & Company (Ad)Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy TranscriptSeptember 14, 2026 | seekingalpha.comCorbus Pharmaceuticals Shares Rise 12% After CANYON-1 Obesity Trial DataSeptember 14, 2026 | finance.yahoo.comCorbus Pharmaceuticals Obesity Drug Avoids 'Depressive Effects'September 14, 2026 | benzinga.comCorbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock UpSeptember 14, 2026 | rttnews.comCorbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of ObesitySeptember 14, 2026 | globenewswire.comSee More Headlines CRBP Stock Analysis - Frequently Asked Questions How have CRBP shares performed this year? Corbus Pharmaceuticals' stock was trading at $8.14 at the start of the year. Since then, CRBP shares have decreased by 15.0% and is now trading at $6.92. How were Corbus Pharmaceuticals' earnings last quarter? Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) posted its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.26) by $0.55. When did Corbus Pharmaceuticals IPO? Corbus Pharmaceuticals (CRBP) raised $20 million in an IPO on Thursday, April 16th 2015. The company issued 20,206,636 shares at a price of $1.00 per share. Who are Corbus Pharmaceuticals' major shareholders? Corbus Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.24%), Engineers Gate Manager LP (0.16%), Pale Fire Capital SE (0.13%) and Seven Fleet Capital Management LP (0.11%). Insiders that own company stock include Yuval Cohen, Dominic Smethurst, Sean F Moran, Nishant C Saxena, Ian Hodgson, Winston Kung, Yong Ben, Anne Altmeyer and John Kenneth Jenkins. View institutional ownership trends. How do I buy shares of Corbus Pharmaceuticals? Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Corbus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Corbus Pharmaceuticals investors own include Visa (V), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Alibaba Group (BABA) and Pfizer (PFE). Company Calendar Last Earnings8/06/2026Today9/28/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 3 weeks, CRBP's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRBP CIK1595097 Webwww.corbuspharma.com Phone(617) 963-0100Fax617-663-6085Employees36Year Founded2009Price Target and Rating Average Price Target for Corbus Pharmaceuticals$41.00 High Price Target$53.00 Low Price Target$30.00 Potential Upside/Downside+492.5%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($6.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$78.54 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.05% Return on Assets-74.22% Debt Debt-to-Equity RatioN/A Current Ratio5.71 Quick Ratio5.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.40 per share Price / Book0.82Miscellaneous Outstanding Shares18,670,000Free Float18,018,000Market Cap$129.20 million OptionableOptionable Beta2.63 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:CRBP) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
